Neurocrine Biosciences (NASDAQ: NBIX) reported Q1 EPS of $0.70, $0.07 worse than the analyst estimate of $0.77. Revenue for the quarter came in at $572.6 million versus the consensus estimate of $593.71 million.

GUIDANCE

INGREZZA Net Product Sales between $2.5-2.6 billion

For earnings history and earnings-related data on Neurocrine Biosciences (NBIX) click here.